RMD · Full Picture

RESMED INC — the full picture

Trailing window · 2026-05-11 to 2026-08-09

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Capital Return Program · Buybacks & dividendsPriority 79
    -14.4% cash (realized); 2 sources (news, press_release); 3 forward row(s); quote_verified
    Guiding to more than $1.85 billion in capital to be returned to shareholders through share repurchases and dividends during FY 2027
  2. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 70
    2 sources (news, press_release); 6 forward row(s); quote_verified
    Announced agreement to sell MatrixCare business; transaction expected to close during the first quarter of Resmed’s fiscal year 2027
  3. Revenue Performance and Mix · Revenue growth & mixPriority 68
    +42.5% revenue (realized); 2 sources (news, press_release); quote_verified
    Fiscal year 2026 revenue increased 10% to $5,653 million (reported as $5,653M / $5.65 billion).
  4. Guidance / Outlook · Guidance & outlookPriority 60
    +3.0% revenue; 2 forward row(s); quote_verified
    Guidance for FY2027 core revenue growth was stated as 5%-7% and non-GAAP EPS guidance of $12 to $12.25.
  5. Operating Margin Drivers · Operating income & profitabilityPriority 56
    +8.4% net_income (realized); quote_verified
    Net income for twelve months ended June 30, 2026: $1,523,293 thousand vs $1,400,723 thousand prior year
  6. Operating Cash Flow Trends · Cash flow generationPriority 55
    2 sources (news, press_release); quote_verified
    ResMed generated $1.6 billion in free cash flow for the full fiscal year.
  7. Income Tax Rate Changes · TaxPriority 54
    quote_verified
    FY 2026 income taxes: $396,123 thousand; FY 2025 income taxes: $276,843 thousand
  8. Astral Ventilator Sales Suspension · UnclassifiedPriority 50
    1 forward row(s); quote_verified
    ResMed's FY2027 guidance assumes no Astral ventilator sales in fiscal 2027, reducing expected revenue by an estimated $75 million.
  9. Geographic Market Commentary · Geographic mixPriority 50
    quote_verified
    Americas Sleep and Breathing Health revenue grew 8% in the fourth quarter
  10. Astral FDA Recall · Regulatory action & investigationsPriority 49
    quote_verified
    ResMed suspended new sales of its Astral ventilator following an FDA recall/field safety action.
  11. Gross Margin Drivers · Gross marginPriority 44
    2 sources (news, press_release); quote_verified
    Three months ended June 30, 2026 cost of sales: $602,431 thousand; gross profit $861,216 thousand
  12. Liquidity and Debt Position · Liquidity & cash positionPriority 43
    +2.9% cash (realized); quote_verified
    Cash and cash equivalents at June 30, 2026: $1,469,234 thousand; at June 30, 2025: $1,209,450 thousand

Threads by pillar

Revenue & Demand Priority 75 · 4 threads

Costs & Margins Priority 62 · 3 threads

Capital & Balance Sheet Priority 85 · 5 threads

Strategy & Portfolio Priority 71 · 2 threads

Legal, Regulatory & Policy Priority 49 · 1 thread

Guidance & Outlook Priority 60 · 1 thread

Macro & Market Conditions Priority 36 · 3 threads

Unclassified Priority 52 · 2 threads

Expected impact by metric

metricforward netforward grossrealized
revenue+3.0%+3.0%+42.5%
cash——-11.5%
net_income——+8.4%